{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-074078","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2024-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.591299+00:00","generated_at":"2026-06-01T02:30:02.970624+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Entrada reports positive Phase 1 data for ENTR-601-44; plans Phase 2 trials in Q4 2024","bullets":["No serious or drug-related adverse events; ENTR-601-44 well-tolerated across all 4 dose cohorts (0.75-6 mg/kg) in 32 healthy volunteers.","At 6 mg/kg, mean exon skipping 0.44% (range 0.3-0.65%), statistically significant vs placebo (p<0.005); muscle concentration mean 53.8 ng/g.","Plans to submit regulatory applications in Q4 2024 for Phase 2 trials of ENTR-601-44 (exon 44) and ENTR-601-45 (exon 45).","ENTR-601-50 Phase 2 trial filing expected in 2025; company sees potential for dosing intervals of at least six weeks."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-074078","json":"https://secwatch.observer/filing/0001104659-24-074078.json","markdown":"https://secwatch.observer/filing/0001104659-24-074078.md","text":"https://secwatch.observer/filing/0001104659-24-074078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000110465924074078/0001104659-24-074078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000110465924074078/tm2417848d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:30:02.970624+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}